Display options
Cite
Lund H, Boysen P, Hope JC, et al. Natural Killer Cells in Afferent Lymph Express an Activated Phenotype and Readily Produce IFN-γ. Front Immunol. 2013;4:395doi: 10.3389/fimmu.2013.00395.
Lund, H., Boysen, P., Hope, J. C., Sjurseth, S. K., & Storset, A. K. (2013). Natural Killer Cells in Afferent Lymph Express an Activated Phenotype and Readily Produce IFN-γ. Frontiers in immunology, 4395. https://doi.org/10.3389/fimmu.2013.00395
Lund, Hege, et al. "Natural Killer Cells in Afferent Lymph Express an Activated Phenotype and Readily Produce IFN-γ." Frontiers in immunology vol. 4 (2013): 395. doi: https://doi.org/10.3389/fimmu.2013.00395
Lund H, Boysen P, Hope JC, Sjurseth SK, Storset AK. Natural Killer Cells in Afferent Lymph Express an Activated Phenotype and Readily Produce IFN-γ. Front Immunol. 2013 Nov 22;4:395. doi: 10.3389/fimmu.2013.00395. eCollection 2013. PMID: 24319444; PMCID: PMC3837235.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2013 Nov 22;4:395. doi: 10.3389/fimmu.2013.00395. eCollection 2013.

Natural Killer Cells in Afferent Lymph Express an Activated Phenotype and Readily Produce IFN-γ.

Frontiers in immunology

Hege Lund, Preben Boysen, Jayne C Hope, Siri K Sjurseth, Anne K Storset

Affiliations

  1. Department of Food Safety and Infection Biology, Norwegian School of Veterinary Science , Oslo , Norway.

PMID: 24319444 PMCID: PMC3837235 DOI: 10.3389/fimmu.2013.00395

Abstract

Natural killer (NK) cells are motile cells that migrate between peripheral blood (PB), lymph nodes (LNs), and various organs. Domestic animals have frequently been used to study cellular migration, and offer unique opportunities for such studies. The aim of this study was to characterize the phenotype and cytokine producing capacity of NK cells in bovine skin-draining lymph. NKp46/NCR1(+) CD3(-) cells constituted 2-11% of mononuclear cells in afferent lymph (AL), a majority of cells were CD16(+), CD8α(+), and CD2(-/low), and elevated CD25 and CD44 expression indicated an activated phenotype. Interestingly, significantly fewer AL NK cells expressed the early activation marker CD69 compared to PB NK cells. A large proportion of lymph and blood NK cells produced interferon (IFN)-γ following stimulation with IL-2 and IL-12. Notably, in AL, but not blood, a similar amount of IFN-γ(+) NK cells was observed when cells were stimulated with IL-12 alone. Overall, AL NK cells were more similar to LN-residing NK cells than those circulating in PB. We conclude that AL appears to be an important migration route for tissue-activated NK cells, and may represent an alternative route for NK cell traffic to LNs. These findings may have important implications in the development of adjuvant strategies that aim to target NK cells in a vaccine response.

Keywords: activation; afferent lymph; bovine; interferon-γ; natural killer cells; trafficking

References

  1. Dev Comp Immunol. 2008;32(7):773-83 - PubMed
  2. Nat Protoc. 2006;1(2):982-7 - PubMed
  3. Dev Comp Immunol. 2004 Jul 1;28(9):941-8 - PubMed
  4. Eur J Immunol. 2013 Jan;43(1):159-69 - PubMed
  5. J Exp Med. 2006 Mar 20;203(3):619-31 - PubMed
  6. Immunology. 1987 Oct;62(2):177-83 - PubMed
  7. Blood. 2003 Apr 15;101(8):3052-7 - PubMed
  8. J Exp Med. 2009 Oct 26;206(11):2469-81 - PubMed
  9. Vet Res. 2009 Nov-Dec;40(6):54 - PubMed
  10. Immunity. 2007 Apr;26(4):503-17 - PubMed
  11. Comp Immunol Microbiol Infect Dis. 2012 May;35(3):219-26 - PubMed
  12. Vet Immunol Immunopathol. 2012 Nov 15;150(1-2):79-89 - PubMed
  13. J Immunol. 2012 Jan 15;188(2):578-84 - PubMed
  14. PLoS One. 2013 Oct 03;8(10):e77334 - PubMed
  15. J Leukoc Biol. 2002 Feb;71(2):173-83 - PubMed
  16. Eur J Immunol. 2006 Jan;36(1):118-28 - PubMed
  17. Ann N Y Acad Sci. 2008;1131:119-33 - PubMed
  18. Br J Dermatol. 1999 Sep;141(3):565-9 - PubMed
  19. J Biol Chem. 2010 Jul 16;285(29):22328-37 - PubMed
  20. Nat Immunol. 2005 Sep;6(9):889-94 - PubMed
  21. J Immunol. 2010 Sep 1;185(5):2808-18 - PubMed
  22. Lymphology. 1973 Mar;6(1):1-5 - PubMed
  23. Vaccine. 2013 Mar 25;31(13):1725-33 - PubMed
  24. Eur J Immunol. 2000 Feb;30(2):491-7 - PubMed
  25. J Invest Dermatol. 2002 Oct;119(4):850-7 - PubMed
  26. Trends Immunol. 2011 Oct;32(10):486-92 - PubMed
  27. PLoS One. 2011 Jan 27;6(1):e16320 - PubMed
  28. Front Immunol. 2012 Nov 20;3:344 - PubMed
  29. J Anat. 1970 Jul;107(Pt 1):87-100 - PubMed
  30. J Immunol. 2004 Sep 15;173(6):3594-8 - PubMed
  31. Nature. 2006 Mar 23;440(7083):540-4 - PubMed
  32. Immunol Lett. 2010 Jun 15;131(1):67-72 - PubMed
  33. J Immunol. 2004 Jan 1;172(1):130-7 - PubMed
  34. Oncologist. 2012;17(10):1256-70 - PubMed
  35. Nat Immunol. 2004 Dec;5(12):1260-5 - PubMed
  36. J Exp Med. 2010 Jun 7;207(6):1283-92 - PubMed
  37. Nat Protoc. 2006;1(2):874-9 - PubMed
  38. Clin Dermatol. 1995 Sep-Oct;13(5):473-83 - PubMed
  39. J Immunol. 2004 Feb 1;172(3):1455-62 - PubMed
  40. Eur J Immunol. 2004 Mar;34(3):669-676 - PubMed
  41. Nat Rev Immunol. 2011 Sep 23;11(10):658-71 - PubMed
  42. Vet Immunol Immunopathol. 2009 Dec 15;132(2-4):101-8 - PubMed
  43. Nat Immunol. 2007 Dec;8(12):1337-44 - PubMed
  44. Front Immunol. 2012 Nov 29;3:347 - PubMed
  45. Nature. 2004 Jan 22;427(6972):355-60 - PubMed
  46. J Immunol. 1998 Aug 1;161(3):1146-55 - PubMed
  47. Trends Immunol. 2012 Jun;33(6):271-80 - PubMed
  48. J Leukoc Biol. 2007 Apr;81(4):968-73 - PubMed
  49. Immunol Rev. 2007 Dec;220:169-82 - PubMed
  50. BMC Immunol. 2006 Apr 27;7:10 - PubMed
  51. J Immunol. 2006 Apr 1;176(7):4331-6 - PubMed
  52. J Exp Med. 1988 May 1;167(5):1572-85 - PubMed
  53. Eur J Immunol. 2012 May;42(5):1261-71 - PubMed
  54. Clin Vaccine Immunol. 2008 Nov;15(11):1666-73 - PubMed
  55. Vet Immunol Immunopathol. 2009 Aug 15;130(3-4):163-77 - PubMed
  56. Arch Dermatol Res. 1992;284(3):123-6 - PubMed

Publication Types